Literature DB >> 14749356

Inhibitory effect of C-type natriuretic peptide (CNP) on cultured cardiac myocyte hypertrophy: interference between CNP and endothelin-1 signaling pathways.

Takeshi Tokudome1, Takeshi Horio, Takeshi Soeki, Kenji Mori, Ichiro Kishimoto, Shin-ichi Suga, Fumiki Yoshihara, Yuhei Kawano, Masakazu Kohno, Kenji Kangawa.   

Abstract

C-type natriuretic peptide (CNP) is known to play a role in the local regulation of vascular tone. We recently found that CNP is also produced by cardiac ventricular cells. However, its local effect on myocyte hypertrophy remains to be elucidated. The present study investigated the effects of CNP on cultured cardiac myocyte hypertrophy and the interaction between CNP and endothelin-1 (ET-1) signaling pathways. CNP attenuated basal and ET-1-augumented protein synthesis, atrial natriuretic peptide secretion, hypertrophy-related gene expression, GATA-4 and MEF-2 DNA binding activities, Ca(2+)/calmodulin-dependent kinase II activity, and ERK phosphorylation. CNP also inhibited ET-1-induced increase in intracellular Ca(2+) concentration. These effects of CNP were mimicked by a cGMP analog, 8-bromo cGMP. However, the inhibitory effects of CNP on the hypertrophic response of myocytes were significantly diminished at high concentrations of ET-1. Although CNP increased intracellular cGMP levels in myocytes, ET-1 suppressed CNP-induced cellular cGMP accumulation. A protein kinase C activator and Ca(2+) ionophore mimicked this suppressive effect of ET-1. We further examined the effect of CNP on the paracrine action of ET-1 secreted from cardiac nonmyocytes. CNP and 8-bromo cGMP significantly inhibited ET-1 secretion from nonmyocytes. Although nonmyocyte-conditioned medium increased the protein synthesis in myocytes through endogenous ET-1 action, this increase was significantly attenuated by pretreatment of nonmyocytes with CNP and 8-bromo cGMP. These findings demonstrate that CNP inhibits ET-1-induced cardiac myocyte hypertrophy via a cGMP-dependent mechanism, and conversely, ET-1 inhibits CNP signaling by a protein kinase C- and Ca(2+)-dependent mechanism, suggesting mutual interference between CNP and ET-1 signaling pathways.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14749356     DOI: 10.1210/en.2003-1260

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  24 in total

Review 1.  Membrane guanylyl cyclase receptors: an update.

Authors:  David L Garbers; Ted D Chrisman; Phi Wiegn; Takeshi Katafuchi; Joseph P Albanesi; Vincent Bielinski; Barbara Barylko; Margaret M Redfield; John C Burnett
Journal:  Trends Endocrinol Metab       Date:  2006-06-30       Impact factor: 12.015

Review 2.  Regulation of blood pressure and salt homeostasis by endothelin.

Authors:  Donald E Kohan; Noreen F Rossi; Edward W Inscho; David M Pollock
Journal:  Physiol Rev       Date:  2011-01       Impact factor: 37.312

Review 3.  Molecular mechanisms underlying cardiac antihypertrophic and antifibrotic effects of natriuretic peptides.

Authors:  Camilla Calvieri; Speranza Rubattu; Massimo Volpe
Journal:  J Mol Med (Berl)       Date:  2011-08-09       Impact factor: 4.599

Review 4.  Natriuretic peptides in cardiometabolic regulation and disease.

Authors:  Nora E Zois; Emil D Bartels; Ingrid Hunter; Birgitte S Kousholt; Lisbeth H Olsen; Jens P Goetze
Journal:  Nat Rev Cardiol       Date:  2014-05-13       Impact factor: 32.419

5.  Guanylyl cyclase (GC)-A and GC-B activities in ventricles and cardiomyocytes from failed and non-failed human hearts: GC-A is inactive in the failed cardiomyocyte.

Authors:  Deborah M Dickey; Daniel L Dries; Kenneth B Margulies; Lincoln R Potter
Journal:  J Mol Cell Cardiol       Date:  2011-11-22       Impact factor: 5.000

Review 6.  The interdependence of endothelin-1 and calcium: a review.

Authors:  Nathan R Tykocki; Stephanie W Watts
Journal:  Clin Sci (Lond)       Date:  2010-07-23       Impact factor: 6.124

Review 7.  Natriuretic peptide receptor B signaling in the cardiovascular system: protection from cardiac hypertrophy.

Authors:  Ines Pagel-Langenickel; Jens Buttgereit; Michael Bader; Thomas H Langenickel
Journal:  J Mol Med (Berl)       Date:  2007-04-12       Impact factor: 4.599

8.  Prolonged effects of B-type natriuretic peptide infusion on cardiac remodeling after sustained myocardial injury.

Authors:  Isaac George; Brad Morrow; Kai Xu; Geng-Hua Yi; Jeffrey Holmes; Ed X Wu; Zhihe Li; Andrew A Protter; Mehmet C Oz; Jie Wang
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-06-12       Impact factor: 4.733

Review 9.  Cyclic GMP signaling in cardiovascular pathophysiology and therapeutics.

Authors:  Emily J Tsai; David A Kass
Journal:  Pharmacol Ther       Date:  2009-03-21       Impact factor: 12.310

Review 10.  C-type natriuretic peptide (CNP): cardiovascular roles and potential as a therapeutic target.

Authors:  Natalie G Lumsden; Rayomand S Khambata; Adrian J Hobbs
Journal:  Curr Pharm Des       Date:  2010       Impact factor: 3.116

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.